Cure My Disease

Don't miss your cure!

 Log in / Sign up

Water pill could boost liver cancer treatment

NCT ID NCT03107416

Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding a common water pill (bumetanide) to a standard procedure that blocks blood flow to liver tumors is safe and might help slow tumor growth. About 30 people with liver cancer that cannot be removed by surgery will take part. The study will first find the safest dose of bumetanide, then check how well it controls the tumor over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bumetanide (a water pill) given directly into the liver artery during a standard procedure to block blood flow to the tumor
What this could lead to
If it works, this could point toward a new way to improve standard embolization for liver cancer, potentially slowing tumor growth.
What could go wrong
This is a very early, small trial (30 people) focused on safety and finding the right dose. It may not show a clear benefit, and the added drug could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

30 people

The number who actually took part.

Started

Apr 2017

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with diagnoses of HCC according to European Association for the Study of Liver disease (EASL) criteria for diagnosis (See Appendix 1). Regional lymphadenopathy will be allowed. * Any virus status accepted (e.g. Hepatitis C etc.) * Any prior liver treatment * Patients within unresectable HCC * At least 18 years old * ECOG performance status 0 or 1 * Radiographically measurable disease per mRECIST 1.1 * Meets standard of care to undergo embolization Exclusion Criteria: * Women who are pregnant or lactating * Documented hypersensitivity to bumetanide or sulfonamides * Patients with resectable HCC * High risk for post-embolization hepatic failure: °Child's C cirrhosis °\> 80% liver involvement by tumor * Contraindication to angiography/embolization including: * Patients cannot receive contrast: * Severe allergic reaction to contrast despite premedication * Poor renal function not on dialysis * Other, based on judgment of the investigator * ECOG score 2 * Main portal vein tumor thrombus * BCLC D = patients with distant metastasis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Unresectable hepatocellular carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Unresectable hepatocellular carcinoma

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Consent and follow-up only)

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Consent and follow-up only)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Consent and follow-up only)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester (Consent and follow-up only)

    Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.